Analytical Profiling of Eliglustat for Gaucher Disease: Method Development and Validation

This review paper comprehensively investigates the analytical profiling of eliglustat, an inhibitor for Gaucher disease. Methodologies employing High-Performance Liquid Chromatography (HPLC), 2D Nuclear Magnetic Resonance (2DNMR), and High-Resolution Mass Spectrometry (HRMS) are explored to elucidate the pharmacodynamic and pharmacokinetic properties of eliglustat. Additionally, it delves into the chemistry, solubility, and mechanism of action of eliglustat. Through a meticulous examination of the available data, this review aims to provide a comprehensive understanding of eliglustat's efficacy and safety profile for the treatment of Gaucher disease. More than 150 papers from eminent institutions doing scientific, technological, and medical research are currently available. The current review effectively outlines the conventional, hyphenated, and distinctive approaches to SFV (structural fingerprinting of variants).